Septerna announced on September 30, 2025 that Dr. Keith Gottesdiener, M.D., will join its board of directors and chair the newly formed R&D Committee. Dr. Gottesdiener brings more than 30 years of experience in biotechnology, having led Prime Medicine through its IPO and overseen the approval of Rhythm Pharmaceuticals’ setmelanotide for rare obesity.
The appointment follows the company’s recent expansion of its pipeline, including the PTH1R hypoparathyroidism program and the SEP-631 mast cell disease candidate. Dr. Gottesdiener's expertise in regulatory strategy and clinical development is expected to accelerate the progression of these programs and support Septerna’s goal of becoming a premier GPCR therapeutics company.
By adding a seasoned executive with a proven track record of moving drugs from discovery to market, Septerna strengthens its governance and signals confidence to investors and partners. The move is anticipated to enhance the company’s ability to navigate complex regulatory pathways and secure future collaborations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.